Currently we make public the recommendations, the key reasons for those recommendations, and a summary of the other information considered by the committee. That document is typically one and a half pages to two pages long. It would provide details concerning the design of the clinical trials and the results of the clinical trials, as well as a comment on the economics and cost-effectiveness of the drug.
We realize--and this in part was addressed in the evaluation of CDR done in 2005--that there can be more transparency. In the coming year, we will be publishing more in-depth reviews of the committee considerations, and those will probably be in the range of 15 to 20 pages, to summarize the clinical and economic aspects of the drug in question.